Genmab has achieved $30 million milestone in its DARZALEX (daratumumab) collaboration with Janssen Biotech, triggered by the first commercial sale of the drug in Europe.   The European Commission recently granted a conditional marketing authorization for first-in-class CD38 immunotherapy DARZALEX as monotherapy for the treatment of relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor (PI) and an immunomodulatory agent and who have demonstrated disease p...